ELCC 2019 | ALK-TKIs: targeted therapies for ALK-positive NSCLC

Antonio Passaro

Antonio Passaro, MD, PhD, of European Institute of Oncology IRCCS, Milan, Italy, discusses the changing treatment landscape for ALK-positive non-small cell lung cancer (NSCLC). Speaking at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Dr Passaro reports that whereas chemotherapy was the major treatment option in the past, newly emerging targeted therapies prompted the introduction of ALK tyrosine kinase inhibitors (TKIs) as the first-line treatment for ALK-positive NSCLC.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter